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Background: Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial
influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into
the barriers and facilitators in buprenorphine adoption.
Methods: We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health
Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators
to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that
county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment
providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with
low and high use of buprenorphine to determine how facilitators and barriers differed between those settings.
Results: County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths,
and prepare providers for participation in integrated models of health care delivery with primary care clinics and
hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use.
Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine,
and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist
pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine
use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates
of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician
prescribing capacity.
Conclusions: This qualitative analysis found that attitudes toward use of medication and medication funding
environment play important roles in an organization’s decision to begin buprenorphine use and that physician
availability influences an organization’s ability to expand buprenorphine use over time.
Additional education, reimbursement support, and policy changes are needed to support buprenorphine
adoption and use, along with a greater understanding of the roles payers, providers, and regulators play in the
adoption of targeted practices.
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Buprenorphine adoption
Buprenorphine is a pharmacotherapy that acts as a par-
tial μ-opiate-receptor agonist [1]. When combined with
naloxone, a full μ-opiate-receptor antagonist that can
counter the effects of opioids, there is diminished poten-
tial for buprenorphine to be abused [2]. Agonist pharma-
cotherapy for opioid dependence (i.e., buprenorphine,
buprenorphine/naloxone combinations, and methadone)
improves retention in addiction treatment and reduces
the use of illicit opioids [3,4]. Until 2002, methadone, a
full μ-opiate-receptor agonist, was the primary pharma-
cotherapy for opioid dependence; however, methadone is
only available in regulated settings that supply limited
take-home medication, and is prone to causing adverse
reactions [5]. Within this environment, buprenorphine
and buprenorphine/naloxone combinations were projected
to play an important role in the treatment of opioid addic-
tion when approved by the Food and Drug Administration
(FDA) in 2002 for use by authorized physicians [6]. Adop-
tion, however, has been slow, especially among publicly-
funded addiction treatment centers; only 17% percent of
specialty treatment centers who accept public funds and
provide outpatient, intensive outpatient, or residential
addiction services offer buprenorphine treatment [7].
Payer role
Payers and regulators, in their oversight role, influence
the structure of treatment systems and the practices
used in treatment centers. Knudsen and Abraham [8]
found that treatment programs were more likely to have
adopted pharmacotherapy for addiction, including but
not limited to buprenorphine, if they perceived greater
support for medications by the Single State Authority
overseeing publicly-funded substance abuse treatment
services. Treatment programs in states that provided
public insurance coverage for buprenorphine were more
likely to provide the medication [9]. The payers’ role is
not limited to reimbursement policy; payers also influ-
ence regulatory policy, contracting requirements, and
provider education [10]. Additionally, payers’ level of
buprenorphine support varies, and few payers apply the
same policy rules to buprenorphine therapy as to they
do to medication therapies common to the treatment of
other chronic disease conditions [11]. Despite payers’ in-
strumental role and mixed support, their perceptions of
facilitators and barriers to buprenorphine use have been
understudied in the health services literature [8,9,12].
Provider facilitators and barriers
Payers contract with treatment agencies (providers) to
provide treatment services, including buprenorphine
treatment. Addiction treatment centers using buprenor-
phine are more likely to be accredited or licensed [11],participate in managed care arrangements [11], provide
detoxification services [9,13,14], employ physicians
[13,15], and offer other medication-oriented treatments
[14,16,17]. A lack of reimbursement for buprenorphine
[18], philosophical resistance to medication therapy [19],
and limited availability of buprenorphine prescribers [7]
inhibit use of buprenorphine in specialty treatment set-
tings. Treatment practitioners’ perceptions of facilitators
and barriers to buprenorphine use and payer priorities
must inform policy if buprenorphine-assisted treatment
is going to reduce opioid addiction and overdose deaths.
Study setting: opioid trends in Ohio
Nationwide, non-medical use of opioids is significantly
influencing public health [20]. Ohio has the 12th highest
drug overdose mortality rate in the United States, and
Ohio has implemented many of the same opioid pre-
scription misuse policies tested in other states [21]. In
2011, 66.7 doses of prescription opioids were purchased
per Ohio citizen, and 1.2 Ohioans died per day due to un-
intentional overdose of prescription opioids [22]. The in-
crease in patients seeking treatment for opioid dependence
challenges Ohio’s publicly-funded system of specialty ad-
diction treatment providers. Ohio treatment providers re-
port that opioid-dependent patients make up more than a
quarter of all clients served, and nearly 80 percent of pro-
viders reported increased wait times for assessment ser-
vices due to increased treatment demand [23].
Ohio currently (2015) provides outpatient methadone
therapy, but is limited to 13 locations. With the small
number of methadone locations, methadone’s limited
take-home availability, and the prevalence of opioid
abuse, buprenorphine treatment is seen as a key strat-
egy for reducing the adverse effects of opioid depen-
dence in Ohio [24]. At present, 22% of Ohio treatment
providers use buprenorphine to support recovery and
43% make referrals to physicians authorized to pre-
scribed buprenorphine [23]. This is higher than the na-
tional buprenorphine use rate of 17% [7], but falls
considerably short of 100% use.
Publicly funded addiction treatment in Ohio is adminis-
tered through Alcohol, Drug Addiction, and Mental
Health Services (ADAMHS) boards (henceforth referred
to as “county boards”) (n = 53) and each board represents
one to five counties. ADAMHS boards support specialty
addiction treatment services using state and local appro-
priations combined with the federal Substance Abuse and
Prevention Treatment (SAPT) block grant. The Substance
Abuse and Mental Health Services Administration
(SAMHSA) provides the SAPT funds, which are intended
for the uninsured and fund up to 55% of addiction treat-
ment services [25]. Within states, counties and other fiscal
intermediaries often perform logical and meaningful roles
in the distribution of addiction funds. In the United States,
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county or regional entities.
The county board structure creates many contrasting
payer environments in Ohio. Our qualitative study com-
pares perceived facilitators and barriers to buprenor-
phine adoption among Ohio’s payers (the county boards)
and providers, and describes why payers and providers




A community trial studied an intervention to increase
use of buprenorphine and other medications for opioid
dependence in Ohio. County boards and substance
abuse treatment provider interviews were conducted
during the pre-implementation phase of this trial [26].
County board participants (N=18) and treatment pro-
vider agency participants (N=36) with greater than 100
admissions per year were recruited (September 1, 2012
to October 31, 2012) and completed the individual inter-
views (November 1, 2012 to February 28, 2013) by tele-
phone. The county boards represented 27 of Ohio’s 88
counties, and these boards support 65 treatment agen-
cies with more than 100 annual admissions. A represen-
tative sample of county board participants was selected,
stratified on 20% opioid admissions of total admissions
(above/below) and 200,000 people covered (above/
below). Three county boards that were not participating
in the trial were interviewed to reduce selection bias. No
other Ohio county boards were approached to partici-
pate in this study. All county boards referred two organi-
zations. These organizations represented 55.4% (36/65)
of the organizations eligible in those county board areas.
Participating counties represented 44.2% (65/315) of all
treatment providers in Ohio with more than 100 admis-
sions per year. No organizations refused to participate in
the qualitative interviews.
For the county board interviews, the board’s highest-
ranking clinical officer or the executive director com-
pleted the interview. These individuals tend to be re-
sponsible for adopting new clinical practices; they also
encounter the facilitators and barriers directly during
clinical practice implementation. Two treatment agen-
cies were interviewed in each county board area to cap-
ture multiple perspectives. A clinical manager with
direct exposure to the facilitators and barriers of the
buprenorphine adoption process completed the agency
interviews.
Data collection procedures
Three members of the research team conducted inter-
views. The principal investigator trained two members
of the research team and observed their first two countyboard and provider interviews. The interview guide was
pilot tested with two county boards and two providers.
The final interview guide addressed knowledge of bar-
riers and facilitators to buprenorphine use for the
county boards and providers. The county boards were
asked whether or not they support buprenorphine use,
and what caused them to support or not support bupre-
norphine adoption. These were asked as general questions,
and no specific issues were solicited. The semi-structured
format allowed for standardization across interviews and
for the interviewer to probe for additional information
when appropriate.
The research team used data from the state’s phar-
macy management and addiction treatment database to
calculate buprenorphine use rates by county (i.e., indi-
viduals with a buprenorphine prescription during 2012
divided by the number of opioid dependent individuals
admitted to the public treatment system by county).
The study received approval from the institutional re-
view boards at the University of Wisconsin–Madison
and the Ohio Department of Health.Data analysis
The review of the qualitative data followed a summative
qualitative content analysis procedure [27]. Interviews
were transcribed for review and four members of the
research team coded the transcripts. The multi-
disciplinary research team (with backgrounds in addic-
tions, operations management, and education) ensured
multiple viewpoints and vigorous discussion of the data.
The first step in the coding process involved open cod-
ing. Transcripts were coded and analyzed using ATLAS.
ti [28]. Two team members coded each transcript inde-
pendently to enhance reliability. An inductive approach
for analyzing qualitative data identified codes and con-
cepts within each interview [29]. Codes and concepts
were grouped by county board and provider. The re-
searchers sought consensus on code nomenclature and
content to ensure more consistent coding. Upon reach-
ing consensus on broad thematic codes and their work-
ing definitions, the team revisited the interviews with
the preliminary coding scheme. At this stage, to ensure
consistency across coders, we examined agreement
across a random selection of interviews. Items with dis-
crepant codes were discussed until consensus was
reached. No coded comments were discarded through-
out the coding process. When coding was complete,
queries of specific codes were generated. Summaries
were generated for the common themes, with examples
of text from each theme. Quotes were chosen to illus-
trate themes expressed by respondents based on clarity,
brevity, variety, and their representation of similar com-
ments from a range of participants.
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Sample characteristics
Listed in Table 1 are the characteristics of the individuals
surveyed, the county boards, and provider agencies.
County board reasons for buprenorphine adoption
All county boards interviewed stated support for the use
of buprenorphine for opioid treatment, with no boards
opposed to use of buprenorphine. County boards re-
ported three reasons for supporting the adoption of
buprenorphine: the escalating rates of opioid depend-
ence/opioid crisis, the need for better care, and integra-
tion with general health care.Table 1 Participant site characteristics – county boards and p
Interviewee site characteristics
County (n = 18)
County board Title












Provider (n = 36)







Physicians on staff Yes
No
Full-time staff equivalents (FTEs) 0-50
51-100
100+
Use of methadone on-site Yes
No
Buprenorphine use Prescribe
Refer to other pro
No use
*Multiple responses were possible.Responding to the opioid crisis: County boards saw
a need to address opioid misuse in their counties be-
cause of the increased demand for detoxification and
care. As one board representative stated:
“We identified this huge increase in opioid addiction
coming through the door. That is what kicked off our
search for what are the best practices out there and
that is how we got involved with buprenorphine and
medication-assisted treatment.” (Board Quote)
Better clinical care: County board respondents
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tention rates, and appealed to younger adults).
“We’re really looking at buprenorphine to get people
retained in treatment until they have the skills to stay
sober in the long term, until they have the recovery
supports around them.” (Board)
Preparing for integration: County boards anticipated
that addiction treatment organizations would need to
offer addiction medication therapy to be part of integrated
care structures where behavioral health (e.g. addiction
treatment and mental health) and general medical (e.g.
primary and hospital care) professional services are coor-
dinated and delivered simultaneously.
“Now is the time to be smart about everything going
into the integration of behavioral health and medical
health. It’s like the train is running and it won’t be too
long before it starts to move and it seems obvious for
medication-assisted therapy to have its body inside
one of the train cars.” (Board)
County board and provider barriers and facilitators
Within a receptive environment for buprenorphine adop-
tion and use, boards and providers identified potential bar-
riers and facilitators to buprenorphine.
County board and provider barriers
Barriers among the county boards and providers were
aggregated into five thematic areas: a) negative atti-
tudes toward the use of agonist pharmacotherapy,
b) lack of awareness/understanding, c) limited phys-
ician availability, d) insufficient funds, and e) diversion
concerns.
Most of the themes and sub-themes were consistent
between the county board and provider respondents,
with few noticeable exceptions. Providers were more
concerned about addiction treatment providers’ lack of
knowledge of buprenorphine, and also about recovery
groups’ hostility toward use of medications for addic-
tion treatment. Representative quotes illustrate the bar-
rier themes and sub-themes, with whether the quote
came from a board or provider interview noted.
A) Negative attitudes toward use of medication
Providers: Staff orientation toward abstinence-based ap-
proaches was often the stated cause of resistance to
medication therapy.
“We have had a pretty big struggle in our community,
philosophically, about some of our providers…that
truly believe that medication-assisted treatment is
substituting one drug for another.” (Board)“I got some staff that are questioning why we would
give a drug to an addict.” (Provider)
Recovery groups: Negative thinking about medication
can extend to recovery groups. Providers have found this
to be a challenge when seeking recovery supports for
patients on pharmacotherapies.
“I think the Alcoholics Anonymous (AA) and Narcotics
Anonymous (NA) community has a lot of prejudice
against opioid maintenance therapy.” (Provider)
“Those in recovery say if you are taking a pill, then
you’re not in recovery.” (Board)
B) Lack of awareness/understanding
Addiction provider not knowledgable about buprenor-
phine: A sub-theme among providers was that buprenor-
phine would be more readily accepted with more training
and a better understanding of buprenorphine.
“I think our staff would like to have more education
beyond just the initial, here is the chemical make-up of
buprenorphine, and here is how it works.” (Provider)
Physicians not knowledgable about buprenorphine:
Physicians not specializing in addiction treatment were
perceived to be possibly administering buprenorphine
without adequate addiction and behavioral health ther-
apy services.
“Most physicians use it [buprenorphine] as they do
other pharmacological aids in the sense, that it is a
pill, rather than wrapping around a holistic approach
with patients.” (Board)
C) Limited physician availability
Physician unwillingness to prescribe buprenorphine:
Physicians reportedly did not want to begin prescribing
buprenorphine because of concerns of working with ad-
diction clientele.
“Doctors do not want to deal with this population.”
(Board)
“We went around to identify different physicians that
would be willing to be involved as a referral site for us
and we got a tremendous amount of negative or
uninterested response.” (Provider)
Limited physician prescribing capacity: Capacity was
constrained by government policy (DATA 2000) [30] allow-
ing physicians to only treat up to 30 patients at a time dur-
ing the first year of certification and 100 patients thereafter.
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can only have 100 patients per prescriber.” (Provider)
“This isn’t unique to [our] county… I’ve run into this
in other counties and even statewide… physicians get
involved, and they get to their 30-patient cap or if
they’re beyond their first year, and they get to their
100-person cap. And then they don’t know how to
discontinue them, and they’re stuck with this immovable
object of a caseload until people start to attrite or they
discontinue.” (Board)
D) Insufficient funds
Insufficient funds for addiction treatment: The
county boards and providers expressed frustration and
concern with the inability to pay for addiction treatment
(with or without buprenorphine) for uninsured patients.
However, when SAPT block grant funds were the only
option for payment for buprenorphine, county boards
and providers expressed a need to preserve existing
therapy-based services instead of reallocating funds for
buprenorphine use.
“Well again it’s the lack of funding, we really don’t have
any money to fund medication-assisted therapy.” (Board)
“We were struggling with funding issues of how it
would be paid for so medications could at least be cost
neutral.” (Provider)
E) Diversion concerns
Diversion Concerns: Concerns about patients selling
their buprenorphine can be a disincentive for organiza-
tions to adopt buprenorphine. These concerns also chal-
lenge existing efforts for those who have adopted
buprenorphine.
“I think that people outside of the clinical community
have this understanding now that buprenorphine has
a street value; the whole issue with diversion. I think it
is what we face the most concerning the medication.”
(Provider)County board and provider facilitators
The facilitators were aggregated into three thematic
areas related to a) providers are knowledgeable (about
buprenorphine); b) criminal justice involvement; and c)
funding. Again, the county boards and providers tended
to share the same perceptions of facilitators. Providers
expressed a much greater appreciation for having access
to physicians who supported buprenorphine use, while
county boards perceived the criminal justice system had
a stronger influence on addiction treatment practices.A) Provider knowledge about buprenorphine
Addiction providers’ knowledge about buprenor-
phine: County boards and providers frequently cited high
levels of provider knowledge as assisting with buprenor-
phine adoption.
“Every single one of our counselors and therapists is
well aware and on board with medication as a
fundamental component of treating certain
addictions.” (Provider)
Specialty physician knowledge about buprenor-
phine: In this provider-dominant theme, physicians dedi-
cated to addiction care were perceived to be knowledgable
about this treatment option.
“I think in terms of the community, those that are
involved with the alcohol and treatment system are
very knowledgable.” (Provider)
B) Criminal justice involvement
Community stakeholder involvement – criminal just-
ice: This predominately county board theme expressed
an appreciation for the criminal justice system’s influ-
ence on addiction treatment practice and policy. The
county boards noted how criminal justice system refer-
rals to addiction treatment programs could facilitate
buprenorphine practice.
“It is most important to have criminal justice system
behind use of buprenorphine. They are just huge in
our county.” (Board)
C) Funding available
County funding for buprenorphine: The county boards
were seen as one of several entities that provided financial
support for buprenorphine use. The counties’ ability to al-
locate tax levy funds (separate from SAPT block grant
funds) to support use of buprenorphine for uninsured
consumers was noted as an important funding source.
“Seventy-five per cent of our funding for buprenorphine
is through our local levy. We could not provide
buprenorphine therapy without these funds.” (Board)
Use of buprenorphine
The last analysis was to discern what themes were
present in county boards that had low or high utilization
of buprenorphine. The county boards had varying
buprenorphine use rates in 2012, with opioid admissions
ranging from 4% to 47% with a mean of 20% (SD 12%).
Four county boards with buprenorphine use rates for
opioid admissions below 10% were compared with four
boards that had rates 30% or greater.
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cerns about negative attitudes toward medication. They
reported that negative attitudes towards buprenorphine
hamper its uptake in the provider community.
“Our providers have considerable resistance to
medication-assisted therapy because it does not follow
12-steps traditions.” (Board)
Boards with high buprenorphine use rates dedicated
funds to purchase buprenorphine, but reported limited
physician availability as a principal barrier.
“We have funds dedicated to buprenorphine therapy,
but cannot always expend them due to a shortage of
physician prescribers.” (Board)
Discussion
The analysis addresses how the increase of opioid mis-
use affects the county boards and providers in Ohio.
The county boards uniformly expressed concerns about
the growing use of prescription and non-prescription
opioids and perceived buprenorphine therapy as a viable
treatment option. Statewide, the county boards in Ohio
prioritize opioid misuse and have policies to address it
[31]. The county boards’ motivation to encourage bupre-
norphine use was based on their fundamental desire for
better clinical care for opioid dependent patients.
It is not uncommon for county boards (or other
payers) and providers to have conflicting opinions on is-
sues related to payment policy, clinical care, quality met-
rics, and necessary treatment capacity [32,33]. However,
in this qualitative assessment, county boards and pro-
viders had similar thoughts on the barriers and facilita-
tors to buprenorphine use. County boards and treatment
providers may be aligned on this issue because they in-
fluence each other’s perceptions and must collaborate on
a response to the opioid crisis and its effect on the ad-
diction treatment system and local communities.
Review of the findings: based on three thematic drivers
Ideology/Knowledge
Ideology precluding use of medication and lack of know-
ledge of the benefits of medication were identified by
study participants as important issues. Long-standing
traditions and firmly held beliefs steeped in 12-step trad-
ition have been found to influence counselor attitudes
towards use of buprenorphine and other medication-
assisted therapies [34]. Yet, the abstinence-only ap-
proach to detoxification and treatment for opioid disor-
ders has not been effective [35]. On the other hand,
medication-assisted therapy possesses an evidence base
that supports greater treatment retention and reduced
use of illicit opioids [4,36]. Hence, those preferring thebehavioral approaches over medication-assisted treat-
ment may be placing ideology over the evidence-base.
Participants’ concerns about anti-medication ideology
extended to physicians as well as to counselors. They felt
that buprenorphine-specific training could help change
attitudes in these key clinical roles.
Physicians
Studies related to physician’s willingness to prescribe
buprenorphine tend to be based on special circum-
stances such as HIV care [37] or focused on primary
care settings [38,39]. Other authors have recommended
that more attention be given to physicians working
within addiction treatment programs [40].
As this analysis explored facilitators and barriers to
buprenorphine use in addiction treatment programs, it
found a complex set of facilitators and barriers to
physician involvement in buprenorphine prescribing
(Figure 1). Barriers began with physicians’ aversion to
addiction care. Respondents mentioned physician con-
cerns about diversion and insufficient time to adopt
buprenorphine prescribing and monitoring into their
practice as additional forces influencing physician
adoption. Facilitating forces, conversely, are based on
physicians being drawn to addiction care.
Funding
Medicaid reimbursement has been associated with greater
use of addiction medications [9,25]. In Ohio, Medicaid
pays for buprenorphine therapy, but a significant number
of patients remain without health insurance to pay for
buprenorphine medication and associated ancillary ser-
vices. This study did confirm the importance of a funding
source for buprenorphine therapy and discovered another
payment source for these medications: use of county tax
levy funds.
Implications
The analysis of high and low buprenorphine use rates
suggests that county funding is a primary driver of
buprenorphine use in Ohio. Accordingly, payers wanting
to expand use of buprenorphine should assure that pay-
ment is available for the buprenorphine medication, as
well as associated physician time, laboratory tests, and
counseling. Our analysis, however, suggests that county
funding is necessary but not sufficient. The implementa-
tion science literature draws a distinction between adop-
tion and implementation of a practice, with adoption
being the first time a person or entity applies the prac-
tice and implementation representing the frequency of
application after adoption [41].
For adoption of buprenorphine in Ohio, it seems that
funding and mindsets are important. The high-use
buprenorphine county board areas had funding for
Figure 1 Physician involvement in buprenorphine prescribing.
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boards areas, oppositional ideologies created barriers
to buprenorphine implementation. Yet, two of the low-
use county boards had county levy dollars available to
support use of buprenorphine. Hence, a combination
of amenable ideology and funding supports may be
needed to create an attractive environment for adop-
tion activities. Buprenorphine-specific training for
counselors and physicians can begin to increase know-
ledge, resulting in counselors who are more likely to
find buprenorphine as acceptable and effective for
treating opioid dependence [42,43].
Physician capacity issues were consistently raised as
an issue in increasing use following adoption. The
DATA 2000 cap of 30 patients per physician in year
one and 100 thereafter [30] creates a clear structural
barrier for physicians working in addiction treatment
settings. This is particularly the case for physicians who
have caseloads of patients on long-term buprenorphine
therapy occupying their existing slots. New physicians
must be recruited once the existing buprenorphine pre-
scribers are treating their allotted number of patients.
This can be difficult when programs must recruit phy-
sicians who do not have a background in addiction
treatment and lends credence to the proposition by
Wood, et al. [44] to provide greater physician education
in addiction medicine. All three of the high volume
buprenorphine county board areas needed additional
physician buprenorphine prescribing capacity, under-
scoring the importance of this factor in promoting
additional buprenorphine use.Study limitations
There are limitations based on the sample. Potential se-
lection bias may exist in the county board sample be-
cause 15 of the 18 county boards that participated in the
qualitative interviews agreed to participate in an inter-
vention study on buprenorphine adoption. The sample
only represents the public treatment system in Ohio.
However, Ohio has been considered to be on the fore-
front of states seeking to remedy non-medical use of
prescription opioids [45].
Another limitation is that many beliefs and attitudes
were attributed to physicians in the analysis. These be-
liefs and attitudes were based on payers’ and providers’
observation from regular interactions with physicians,
yet were not directly provided by practicing physicians.
Additional analyses of buprenorphine beliefs and atti-
tudes should include physicians in the sample to deter-
mine how their perspectives compare to those of payers
and providers.
Lastly, the interviews were conducted with a limited
group of key decision makers from the county boards and
provider organizations. While we assumed their comments
were representative of issues occurring in the environment,
a greater set of interviews within the organizations surveyed
as well as other organizations could provide additional in-
put for consideration.
Conclusions
Our study was specific to Ohio, but barriers and facilita-
tors are not unique to this state. This research suggests
initial adoption of buprenorphine requires funding and
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equate physician capacity. Education can increase know-
ledge and reduce prejudices against medication-assisted
treatment, and policy can play a role in funding supports
and physician capacity. Ongoing efforts to promote
buprenorphine reimbursement and to remove the phy-
sician prescribing caps could help expand use. Lastly,
continuing to develop a greater understanding of the
unique roles of payers, providers, and regulatory bodies
will promote adoption and implementation of buprenor-
phine and other evidence-based practices.
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